Not available outside of the UK & Ireland.
Application
MBX-102 may be used in PPAR-mediated cell signaling studies.
Biochem/physiol Actions
MBX-102 has a potent transrepression effect on PPARγ. It is an oral glucose-reducing agent and also has insulin-sensitizing properties. It is useful as treatment for type 2 diabetes. MBX-102 also lowers triglycerides in a PPARα-independent manner.
MBX-102 is a selective PPAR modulator (SPPARM) and has been shown to inhibit phosphorylation of PPARγ. MBX-102 is converted to the active form, MBX-102 acid, in vivo.
Features and Benefits
This compound is featured on the Nuclear Receptors (Non-Steroids) and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Packaging
5, 25 mg in glass bottle
This product has met the following criteria to qualify for the following awards: